Who Exports Pomalidomide from India — 108 Suppliers Behind a $4.4M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for pharmaceutical manufacturing. The city hosts Genome Valley, India's first biotech cluster, which accommodates over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy's Laboratories, Aurobindo Pharma, and Divi's Laboratories. This concentration fosters advanced research and development, particularly in active pharmaceutical ingredients (APIs), vaccines, biologics, and biosimilars. The presence of esteemed institutions like the National Institute of Pharmaceutical Education and Research (NIPER) and the Indian Institute of Chemical Technology (IICT) further enhances the region's talent pool and innovation capacity.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its robust pharmaceutical manufacturing ecosystem, contributing nearly 28% of India's pharma production. This region is home to prominent companies such as Zydus Cadila, Intas Pharmaceuticals, Torrent Pharmaceuticals, and Cadila Pharmaceuticals. The area's well-developed infrastructure, including efficient transportation networks and supportive regulatory frameworks, facilitates large-scale production of pharmaceutical formulations. The Gujarat government's proactive policies and incentives have further bolstered the region's attractiveness for pharmaceutical investments.

The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical gateway for pharmaceutical exports, leveraging its strategic coastal location and proximity to major ports. This region hosts a dense concentration of pharmaceutical companies, including Cipla, Glenmark Pharmaceuticals, and Lupin Limited. The well-established logistics and export infrastructure in this area facilitate efficient distribution of pharmaceutical products to international markets. Additionally, the presence of regulatory bodies and testing laboratories ensures compliance with global quality standards, enhancing the region's reputation as a reliable export hub.

Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives and government policies. The region hosts over 1,000 pharmaceutical manufacturing units, making it one of the largest pharma hubs in Asia. Companies such as Cipla, Dr. Reddy's Laboratories, and Cadila Healthcare have established substantial operations here. The area's strategic location, coupled with cost-effective manufacturing capabilities, has attracted both domestic and multinational pharmaceutical firms.

• Diversify Supplier Base: While MSN Laboratories Private Limited dominates Pomalidomide exports, consider engaging with other established suppliers such as NATCO Pharma Limited and Hetero Labs Limited to mitigate supply chain risks.

• Leverage Regional Strengths: Utilize Hyderabad's expertise in API production for sourcing raw materials and Ahmedabad-Vadodara's capabilities in formulations for finished products to optimize the supply chain.

• Optimize Export Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to ensure efficient and timely delivery of pharmaceutical products to international markets.

• Evaluate Cost Benefits: Assess the financial advantages of manufacturing in tax incentive zones like Baddi-Nalagarh to reduce production costs and enhance competitiveness in the global market.